3-(1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide | 1338320-95-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3-(1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
• 英文别名: (E)-N-hydroxy-3-[1-(4-methoxyphenyl)sulfonyl-2,3-dihydroindol-5-yl]prop-2-enamide
• CAS: 1338320-95-8
• 化学式: C₁₈H₁₈N₂O₅S
• 分子量: 374.4
• InChiKey: LMFNVOGHSBJWLX-YCRREMRBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS
  申请人：Chen Ching-Shih

  公开号：US20110245315A1

  公开（公告）日：2011-10-06

  Indolyl or indolinyl compounds of formula (I): wherein bond, n, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 , are defined herein. Also disclosed is a method for treating cancer with these compounds.

  式(I)的吲哚基或吲哚啉基化合物： 其中 键，n，R1，R2，R3，R4，R5和R6在此定义。还公开了一种使用这些化合物治疗癌症的方法。
• INDOLINE COMPOUNDS FOR TREATMENT AND/OR PREVENTION OF INFLAMMATION DISEASES
  申请人：Taipei Medical University

  公开号：US20150368195A1

  公开（公告）日：2015-12-24

  The invention is based on the discovery that 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines and 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles has great potential as a novel agent to be used in the treatment of inflammation-associated diseases, particularly, inflammatory arthritis and fibrosis.

  该发明基于发现，1-芳基磺酰基-5-(N-羟基丙烯酰胺)吲哚和1-芳基磺酰基-5-(N-羟基丙烯酰胺)吲哚具有作为一种新型药物用于治疗炎症相关疾病的巨大潜力，特别是炎性关节炎和纤维化。
• Indoline derivatives for treatment and/or prevention of fibrosis diseases
  申请人：Taipei Medical University

  公开号：US11278523B2

  公开（公告）日：2022-03-22

  The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

  本发明涉及吲哚啉衍生物的使用，以及其在预防和/或治疗纤维化疾病中的有效剂量。该化合物能够在无细胞毒性和基因毒性的条件下，有效预防和/或治疗纤维化疾病。
• METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
  申请人：Design Therapeutics, Inc.

  公开号：US20210238226A1

  公开（公告）日：2021-08-05

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2br tbp, htt, jph3r ar, or atn1 and treating diseases and conditions in which dmpk, atxn1, atxn2, atxn3, cacna1a, atxn1, ppp2r2b, tbp, htt, jph3, ar, or atn1 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.
• INDOLINE DERIVATIVES FOR TREATMENT AND/OR PREVENTION OF FIBROSIS DISEASES
  申请人：Taipei Medical University

  公开号：US20220184032A1

  公开（公告）日：2022-06-16

  The invention relates to the use of Indoline derivatives, and their effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.